Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Epiruba-50
Drug International Ltd.
Generic: Epirubicin Hydrochloride
Safety Advices
বাংলা
English
UNSAFE
It is unsafe to consume alcohol with Epiruba-50.
CONSULT YOUR DOCTOR
Epiruba-50 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Epiruba-50 is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Epiruba-50 may cause side effects which could affect your ability to drive.
Epiruba-50 may cause episodes of nausea and vomiting, which can temporarily lead to an impairment of the ability to drive.
SAFE IF PRESCRIBED
Epiruba-50 is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Epiruba-50 may not be needed in these patients. Please consult your doctor.
Lower doses may be considered in patients with serum creatinine > 5 mg/dL.
CAUTION
Epiruba-50 should be used with caution in patients with liver disease. Dose adjustment of Epiruba-50 may be needed. Please consult your doctor.
Use of Epiruba-50 is not recommended in patients with severe liver disease.
Medicine Overview of Epiruba-50 2mg/ml Injection
Introduction
Epiruba-50 is used in the treatment of various types of cancers of blood, breast, stomach, lung, ovaries and soft tissues. It also helps to prevent the recurrence of bladder cancer after surgery. It is given as a drip or infusion vein with extreme caution by a qualified medical professional. It can be used alone, or sometimes given together with certain other medicines as part of combination chemotherapy. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time....
... Show moreUses of Epiruba-50
- Cancer
Side effects of Epiruba-50
Common
- Low blood platelets
- Nausea
- Hair loss
- Absence of menstrual periods
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Weight loss
- Decreased white blood cell count (neutrophils)
- Hot flashes
- Gastrointestinal inflammation
- Rash
- Low energy
- Eye disorder
How to use Epiruba-50
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Epiruba-50 works
Epiruba-50 is an anti-cancer medication. It works by suppressing the activity of an enzyme (topoisomerase II) involved in DNA multiplication of the breast cancer cells. It also forms harmful chemicals (free radicals) which cause DNA damage. This slows the growth of breast cancer cells and eventually kills them.
Quick Tips
- Epiruba-50 is used alone or in combination with other medicines for the treatment of various types of cancers.
- It is given through a drip into a vein (intravenous infusion) by a doctor or nurse.
- It may make you feel tired or sleepy. Do not drive or do anything that requires mental focus until you know how it affects you.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for 6 months after stopping treatment.
- Your doctor may get regular blood tests done to monitor your blood cells, liver, and heart function during treatment with this medicine.
- Inform your doctor immediately if you notice any signs of infection such as fever, sore throat or rash.
Brief Description
Indication
Acute leukaemias; Lymphoma; Multiple myeloma, Breast cancer, Bladder carcinoma
Administration
IV Administration
Administer infuse into tubing of a freely flowing infusion (NS or D5W) over 3-5 min
Avoid extravasation, associated with severe ulceration & soft tissue necrosis; flush with 5-10 mL of IV solution before & after drug administration
Adult Dose
Adjuvant Breast Cancer Treatment Option 1 (Day 1 dose schedule) Day 1: Epirubicin 100 mg/m² IV, AND 5-fluorouracil 500 mg/m² IV, AND cyclophosphamide 500 mg/m² IV Repeat q21Days x 6 cycles Option 2 (Divided dose schedule) First dose divided equally between days 1 & 8: Epirubicin 60 mg/m² IV, AND 5-fluorouracil 500 mg/m² IV, AND Days 1-14: Cyclophosphamide 75 mg/m² PO Repeat q28Days x 6 cycles Intravenous Lymphoma; Multiple myeloma; Solid tumours; Acute leukaemias Adult: As a single agent: 60-90 mg/m2 every 3-4 wk. May divide dose over 2-3 days if desired. May admin as an inj over 3-5 minutes...
... Show moreChild Dose
Safety & efficacy not established
Renal Dose
Renal Impairment
SCr >5 mg/dL [>442 micromoles/L]: Decrease dose by 50%; test cardiac ejection fraction via MUGA before starting treatment
Contraindication
Cardiac impairment, severe or recent MI; previous full cumulative doses of anthracyclines. Hypersensitivity; severe hepatic dysfunction. Not for intravesical use where invasive tumours have penetrated the bladder wall; urinary infections, bladder inflammation or catheterisation problems. Pregnancy, lactation.
Mode of Action
Epirubicin, an anthracycline with cytotoxic properties. It inhibits DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs that triggers DNA cleavage by by topoisomerase II. It also inhibits DNA helicase and generates cytotoxic free radicals.
Precaution
Previous extensive radiotherapy, bone infiltration by tumour, severe renal and hepatic dysfunction. May cause tumor lysis syndrome or radiation recall. Elderly women >70 yr. CV disease, hypertensive cardiomyopathy; monitor hematological and cardiac function regularly. Extravasation during IV admin may result in severe local tissue necrosis. Do not give via IM/SC routes as extravasation can lead to severe local necrosis.
Lactation: not known if excreted in breast milk; do not nurse
Side Effect
>10%
Alopecia (96%),Nausea and vomiting (92%),Leukopenia or neutropenia (80%),Amenorrhea (72%),Anemia (72%),Mucositis (59%),Thrombocytopenia (49%),Lethargy (46%),Hot flashes (39%),Diarrhea (25%),Conjunctivitis (15%)
1-10%
Rash (9%),Fever (5%),Skin changes (5%),Anorexia (3%)
<1%
Acute lymphoid leukemia,Acute myelogenous leukemia,Atrioventricular block,Esophagitis,Hyperpigmentation,Myelodysplastic syndrome
Frequency Not Defined
Myocardial toxicity (including CHF),Severe myelosuppression,Risk of secondary AML
Pregnancy Category Note
Pregnancy Verify pregnancy status in female patients of reproductive potential prior to initiating Based on findings from animal studies and mechanism of action, drug can cause fetal harm when administered to a pregnant woman; avoid use during the 1st trimester Available human data do not establish presence or absence of major birth defects and miscarriage related to use during the 2nd and 3rd trimesters; there are reports of fetal and/or neonatal cardiotoxicity following in utero exposure to epirubicin There have been rare reports of fetal and/or neonatal transient ventricular hypokinesia, transient elevation of cardiac enzymes, and a case of fetal...
... Show moreInteraction
Paclitaxel and other anthracyclines. Cimetidine, heparin. Antineoplastic drugs, cardiotoxic drugs, radiation, hepatoactive drugs.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register